What Aflamin Treats: Main Uses and Benefits

---

The primary purpose of Aflamin (Aceclofenac) is to provide symptomatic relief by addressing the core manifestations of symptoms related to physical discomfort and inflammation across several clinical domains.

The medication is commonly used across domains involving inflammatory or irritative states. It is relevant for easing the symptom clusters of major conditions such as Rheumatoid Arthritis (RA), Osteoarthritis (OA), and Ankylosing Spondylitis (AS). Additionally, it is relevant for easing acute, localized discomfort like dental pain, musculoskeletal discomfort, and soft tissue conditions like extraarticular rheumatism.

For symptoms that interfere with daily functioning such as persistent joint pain, tenderness, and symptoms that create noticeable physiological strain, Aflamin provides support that helps ease the overall symptom burden.

“This medication may assist with maintaining functional stability when symptoms interfere with routine activities.”

The medication is used in scenarios where short-term symptomatic assistance is needed, and it supports general well-being during symptomatic phases.

Quick Fact: Relief for Pain, Stiffness, and Swelling
Aflamin is commonly used to help with the cluster of symptoms defined by pain, inflammation, and accompanying joint stiffness across various musculoskeletal and rheumatic conditions.

Regulatory References

1. Official Product Summary for Aceclofenac

Aflamin (Aceclofenac) is subject to strict eligibility rules documented in official regulatory labeling. Use is generally established for adults, but is contraindicated in several key populations.

Contraindicated Populations

The medicine must not be used by patients with a history of NSAID-induced hypersensitivity (e.g., asthma or urticaria), active or recurrent gastrointestinal bleeding or ulceration, or any active bleeding disorder. Use is also strictly prohibited in patients with severe organ impairment, including severe hepatic, severe renal, or severe heart failure (NYHA II–IV), and in those with established cardiovascular diseases (e.g., ischemic heart disease).

Age and Physiological Restrictions

Population Group	Official Eligibility Status
Children/Adolescents (Under 18)	Not recommended (lack of clinical data)
Third Trimester of Pregnancy	Contraindicated
Lactation/Breastfeeding	Not recommended (should be avoided)

For elderly patients and individuals with mild to moderate hepatic or renal impairment, treatment requires caution and close medical surveillance, as regulatory documents indicate an increased risk of serious adverse reactions in these groups.

Aflamin (Aceclofenac) interacts with several medicinal products and substances, primarily through altering drug exposure or creating additive risks to specific organ systems, as documented in official regulatory labels.

Contraindicated Combinations and Restrictions

Co-administration with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including aspirin and COX-2 inhibitors, is strictly avoided due to a documented increase in the risk of adverse effects, particularly gastrointestinal bleeding. Consumption of alcohol must also be avoided due to its documented effect of increasing the risk of gastrointestinal bleeding.

Exposure and Efficacy Alterations

Aceclofenac may officially increase the plasma concentrations of certain co-administered drugs. This pharmacokinetic effect is specifically documented for Lithium, Digoxin, and Methotrexate, where reduced renal clearance can lead to elevated levels. Conversely, the anti-hypertensive effects of agents like ACE-Inhibitors and ARBs, as well as the effects of Diuretics, may be reduced.

Additive Risk Interactions

Combining Aflamin with systemic Corticosteroids, Anti-platelet agents, or SSRIs is associated with an increased risk of gastrointestinal ulceration and bleeding. Co-administration with Ciclosporin or Tacrolimus carries a documented increased risk of nephrotoxicity. These interactions structure the profile around mitigating additive risks to the gastrointestinal and renal systems.

Timing-Based Constraints

Specific timing rules apply to certain combinations as a procedural constraint. Aflamin should not be used for 8 to 12 days following administration of Mifepristone. Caution is required if Methotrexate is administered within a 24-hour window.

Aflamin's mechanism involves the concurrent action of three distinct components, targeting key pathways of prostaglandin synthesis and inflammatory exudate accumulation.

Blocking Chemical Pain and Inflammation Signals

This core mechanism involves the primary component, aceclofenac, which acts as an inhibitor of the Cyclooxygenase (COX) enzymes. By blocking these key enzymes, the drug prevents the conversion of a precursor molecule into prostaglandins , which are chemical mediators that sensitize nerve endings and increase vascular permeability and fluid accumulation. This action modulates peripheral pain signal transmission and alters the inflammatory cascade at the mediator synthesis level.

️ Adjusting Central Body Temperature Regulation

A second component, paracetamol, acts primarily in the Central Nervous System (CNS) to influence the body's heat control center in the hypothalamus. This central action may modify the thermal set-point by altering prostaglandin levels in the brain. This engagement with the thermoregulatory pathway modifies the activity of the central thermal set-point.

Facilitating the Resolution of Exudate Components

The third unique component, serratiopeptidase, is an enzyme that works to physically process the products of inflammation. It acts as a protease, breaking down specific non-viable proteins, like fibrin, that accumulate in the tissue fluid (exudate). This proteolytic activity decreases the viscosity of the inflammatory exudate and promotes the breakdown of fibrin-related protein structures.

Aflamin is administered via the oral route, using tablets or capsules, or through the topical route with a cream or gel, depending on whether systemic or localized action is required. The standard oral dosing regimen for adults involves a total daily amount of 200 mg of Aceclofenac, routinely administered as two separate 100 mg units, establishing a twice-daily frequency.

To ensure proper administration, oral tablets must be swallowed whole with an adequate amount of liquid and must not be crushed or chewed. Dosing instructions permit the oral dose to be taken with or immediately after food to potentially enhance gastrointestinal tolerance. The fundamental principle guiding its use is to employ the lowest effective dose for the shortest duration necessary for symptomatic control. Long-term use requires periodic clinical re-evaluation of the need for continued therapy.

For the topical formulation, the usage pattern involves applying the gel or cream up to three times per day directly to the affected area. The treated area should not be covered with an occlusive dressing.

Dosing modifications are specified for certain populations. Patients with mild to moderate hepatic impairment are typically instructed to commence treatment with a reduced daily dose of 100 mg, and the medication is not recommended for use in children due to insufficient clinical data.

Research Evidence / Overview of Studies for Aflamin (Aceclofenac)

This section provides an overview of the research evidence and study structure used to evaluate Aceclofenac, the active ingredient in Aflamin. The information is derived only from official regulatory and peer-reviewed scientific sources and focuses on the types of trials conducted and the outcomes that were measured, without offering clinical advice.

---

Research Evidence for Osteoarthritis (OA)

Research exploring the symptomatic profile of Aceclofenac in adults with Osteoarthritis (OA) has relied on Randomized Controlled Trials (RCTs) and analyses that combine findings from multiple studies. These trials were designed to examine outcomes related to physical discomfort and measures of daily functioning.

Studies primarily monitored changes in pain intensity and objective measures of function, such as the WOMAC Index, over defined time intervals, often lasting between 4 and 12 weeks. The evidence base includes reports where measurements were observed across multiple short-term trials involving the target adult population. However, follow-up durations were limited in most of the core efficacy studies, meaning long-term changes are not fully established by the existing RCT data.

---

Research Evidence for Inflammatory Rheumatic Conditions (RA and AS)

Aceclofenac was also evaluated in clinical trials involving patients with chronic inflammatory conditions, specifically Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS). These studies explored symptomatic patterns using outcomes linked to inflammatory or irritative states.

For RA, studies monitored the number of tender and swollen joints. For AS, research examined measures of spinal mobility and function (e.g., BASFI scores). The data show patterns related to how symptoms evolved in the observed populations during the study periods, which were typically medium-term (around 12 weeks). The evidence base is noted to be generally smaller for AS compared to OA, and studies primarily focus on short-term symptom patterns.

Common questions about Aflamin (FAQ)

Q: What is Aflamin, and how does it work?

A: Aflamin is a brand name for the medicine containing aceclofenac. It belongs to a group of medicines called non-steroidal anti-inflammatory drugs (NSAIDs). It works by reducing the production of certain chemicals in the body, primarily prostaglandins, which are responsible for causing pain and inflammation.

Aceclofenac is used to relieve pain and swelling in conditions such as:

• Osteoarthritis (a condition affecting joints)
• Rheumatoid arthritis (a long-term disease causing joint inflammation)
• Ankylosing spondylitis (a type of spinal arthritis)

Q: How should I take Aflamin?

A: Always follow your doctor's instructions exactly for taking Aflamin. Generally, the tablets should be swallowed whole with a glass of water, usually during or after a meal. Taking it with food can help reduce the chance of stomach upset.

• Do not crush, chew, or break the tablets.
• It's important to take the lowest effective dose for the shortest possible time to minimize side effects.
• If you forget a dose, take it as soon as you remember, unless it is almost time for your next dose. Do not take a double dose to make up for a missed one.

Q: What are the common side effects of Aflamin (aceclofenac)?

A: Like all medicines, Aflamin can cause side effects, although not everyone gets them. Common side effects often affect the digestive system and may include:

• Upset stomach or indigestion (dyspepsia)
• Stomach pain
• Nausea (feeling sick)
• Diarrhea

Less commonly, other side effects can occur, such as a risk of developing a stomach or intestinal ulcer. If you experience severe or worrying symptoms, you should consult your doctor immediately.

Q: Can Aflamin be taken with other pain relievers?

A: You should not take Aflamin (aceclofenac) at the same time as other NSAIDs, including other prescription medicines and over-the-counter NSAIDs like ibuprofen or naproxen. This significantly increases the risk of serious side effects, especially those affecting the stomach and intestines.

It is generally safe to take Aflamin with simple pain relievers like acetaminophen (paracetamol) if your doctor advises it, but you should always inform your doctor or pharmacist about all the medicines, supplements, or herbal products you are currently taking to check for any potential interactions.

Q: Who should not take Aflamin?

A: Aflamin is not suitable for everyone. You must not take Aflamin if you have:

• A known allergy to aceclofenac, aspirin, or any other NSAID.
• An active or history of recurrent stomach or intestinal ulcers or bleeding.
• Severe kidney or liver problems.
• Severe heart failure or established heart disease (such as after a heart attack or stroke).
• Bleeding problems or conditions that increase the risk of bleeding.
• You are in the last three months of pregnancy.

Always discuss your full medical history with your doctor before starting this medication.

How to Store and Dispose of Aflamin?

The storage and disposal requirements for Aflamin (acemetacin) are defined by regulatory guidance to ensure stability, safety, and proper environmental handling.

Storage Component	Official Requirement
Temperature	Store at controlled room temperature (typically 20 C to 25 C).
Protection	Keep the medication in the original container, tightly closed, and protect from excess heat and moisture (do not store in the bathroom).
Safety	Keep out of sight and reach of children; store the medication up and away in a secure location.

For disposal, it is important to prevent accidental exposure and environmental contamination. Do not flush unneeded Aflamin down the toilet. Dispose of the medication using a formal drug take-back program when possible, or secure it in the household trash after mixing it with an undesirable substance like dirt or used coffee grounds.